Long-term outcomes of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer: a prospective phase II study - Scorecard - MDSpire
Advertisement
Long-term outcomes of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer: a prospective phase II study
Clinical Scorecard: Long-term Results of Definitive Chemoradiotherapy Using Docetaxel, Cisplatin, and 5-Fluorouracil for Postoperative Locoregional Recurrence of Esophageal Cancer: Findings from a Phase II Prospective Study
At a Glance
Category
Detail
Condition
Postoperative locoregional recurrence of esophageal cancer
Key Mechanisms
Definitive chemoradiotherapy (CRT) using docetaxel, cisplatin, and 5-fluorouracil (DCF)
Target Population
Patients aged 20 to 75 years with postoperative locoregional recurrence without distant metastasis
Care Setting
Single-arm, prospective phase II trial
Key Highlights
Median progression-free survival (PFS) of 48.0 months
3-year and 5-year PFS rates of 55.2% and 49.7%, respectively
3-year and 5-year overall survival (OS) rates of 75.2% and 58.8%, respectively
High treatment compliance with 89.7% completing the regimen without dose reduction
Favorable safety profile with no grade ≥2 late adverse events
Guideline-Based Recommendations
Diagnosis
Comprehensive diagnosis using upper gastrointestinal endoscopy, ultrasonography, CT, and FDG-PET
Management
Administer DCF-based chemoradiotherapy with 60 Gy radiotherapy and concurrent chemotherapy
Monitoring & Follow-up
Monitor for treatment-related toxicities and adjust treatment as necessary
Risks
Grade 4 hematologic toxicities in 3 patients and one case of grade 3 heart failure
Patient & Prescribing Data
29 patients enrolled between 2015 and 2023
High compliance and manageable toxicity profile observed
Clinical Best Practices
Utilize three-dimensional conformal radiotherapy (3D-CRT) for involved-field radiotherapy
Ensure adequate patient selection based on performance status and absence of distant metastasis
Monitor hematologic parameters closely during chemotherapy cycles
